PDGFRA and ischemic stroke: Toward that goal, the recent phase II clinical trial testing the safety of the PDGFRα antagonist Imatinib in patients treated with intravenous thrombolysis after ischemic stroke has demonstrated that Imatinib is safe following thrombolysis and improves neurological outcomes [66].